Rac-induced left ventricular dilation in thyroxin-treated zmracd transgenic mice: Role of cardiomyocyte apoptosis and myocardial fibrosis

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Elnakish, Mohammad T ^a   Hassona, Mohamed D H ^a   Alhaj, Mazin A ^a   Moldovan, Leni ^a   Janssen, Paul M L ^a   Khan, Mahmood ^a   Hassanain, Hamdy H ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; CASPASE 3; CASPASE 8; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PRAVASTATIN; RAC PROTEIN; SUPEROXIDE; THYROXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE MODEL; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARBAZOLES; CARDIOMEGALY; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; FEMALE; FIBROSIS; MALE; MICE; MICE, TRANSGENIC; MYOCARDIUM; MYOCYTES, CARDIAC; PRAVASTATIN; PROPANOLAMINES; RAC GTP-BINDING PROTEINS; THYROXINE; VASODILATOR AGENTS;

EID: 84865287230     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042500     Document Type: Article

References (61)

1. Heineke J, Molkentin JD, (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7: 589-600.
2. Klein L, O'Connor CM, Gattis WA, Zampino M, de Luca L, et al. (2003) Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardiol 91: 18F-40F.
3. Lips DJ, deWindt LJ, van Kraaij DJ, Doevendans PA, (2003) Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J 24: 883-896.
4. Berenji K, Drazner MH, Rothermel BA, Hill JA, (2005) Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol 289: H8-H16.
5. Diwan A, Dorn GWII, (2007) Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. Physiology 22: 56-64.
6. Selvetella G, Hirsch E, Notte A, Tarone G, Lembo G, (2004) Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. Cardiovasc Res 63: 373-380.
7. Dorn GW, (2009) Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol 6: 283-291.
8. Rose BA, Force T, Wang Y, (2010) Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev 90: 1507-1546.
9. Lezoualc'h F, Metrich M, Hmitou I, Duquesnes N, Morel E, (2008) Small GTP-binding proteins and their regulators in cardiac hypertrophy. J Mol Cell Cardiol 44: 623-632.
10. Sussman MA, Welch S, Walker A, Klevitsky R, Hewett TE, et al. (2000) Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. J Clin Invest 105: 875-886.
11. Maack C, Kartes T, Kilter H, Schäfers HJ, Nickenig G, et al. (2003) Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 108: 1567-1574.
12. Elnakish MT, Awad MM, Hassona MD, Alhaj MA, Kulkarni A, et al. (2011) Cardiac Remodeling Caused by Transgenic Over-expression of a Corn Rac Gene. Am J Physiol Heart Circ Physiol 301: H868-H880.
13. Frey N, Olson EN, (2003) Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65: 45-79.
14. Pierres C, Gaugain-Hamidi A (2009) Concentrated Liquid Thyroid Hormone Composition. Patentdocs website. Available: http://www.faqs.org/patents/app/20090270507#ixzz1R067AyTq. Accessed: 2012 August 3.
15. Pfeffer MA, Braunwald E, (1990) Ventricular remodeling after myocardial infarction. Circulation 81: 1161-1172.
16. Schaefer WH, Politowski J, Hwang B, Dixon F Jr, Goalwin A, et al. (1998) Metabolism of carvedilol in dogs, rats, and mice. Drug Metab Dispos 26: 958-969.
17. Watanabe K, Ohta Y, Nakazawa M, Higuchi H, Hasegawa G, et al. (2000) Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br J Pharmacol 130: 1489-1495.
18. Samuel MS, Lourenço FC, Olson MF, (2011) K-Ras mediated murine epidermal tumorigenesis is dependent upon and associated with elevated Rac1 activity. PLoS One 6: e17143.
19. Hassona MD, Elnakish MT, Abouelnaga ZA, Alhaj M, Wani AA, et al. (2011) The Effect of Selective Antihypertensive Drugs on the Vascular Remodeling-associated Hypertension: Insights from a Profilin1 Transgenic Mouse Model. J Cardiovasc Pharmacol 57: 550-558.
20. Feuerstein GZ, Ruffolo RR Jr, (1996) Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J 17: 24-29.
21. Balakumar P, Singh M, (2006) The possible role of caspase-3 in pathological and physiological cardiac hypertrophy in rats. Basic Clin Pharmacol Toxicol 99: 418-424.
22. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, et al. (2003) A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 111: 1497-1504.
23. Aikawa R, Nitta-Komatsubara Y, Kudoh S, Takano H, Nagai T, et al. (2002) Reactive oxygen species induce cardiomyocyte apoptosis partly through TNF-alpha. Cytokine 18: 179-183.
24. Kuzman JA, O'Connell TD, Gerdes AM, (2007) Rapamycin prevents thyroid hormone-induced cardiac hypertrophy. Endocrinology 148: 3477-3484.
25. Siwik DA, Tzortzis JD, Pimental DR, Chang DL, Pagano PJ, et al. (1999) Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. Circ Res 85: 147-153.
26. Pimentel DR, Amin JK, Xiao L, Miller T, Viereck J, et al. (2001) Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res 89: 453-460.
27. Araujo AS, Schenkel P, Enzveiler AT, Fernandes TR, Partata WA, et al. (2008) The role of redox signaling in cardiac hypertrophy induced by experimental hyperthyroidism. J Mol Endocrinol 41: 423-430.
28. Florini JR, Saito Y, Manowitz EJ, (1973) Effect of age on thyroxin-induced cardiac hypertrophy in mice. J Gerontol 28: 293-297.
29. Kuzman JA, Vogelsang KA, Thomas TA, Gerdes AM, (2005) L-Thyroxine activates Akt signaling in the heart. J Mol Cell Cardiol 39: 251-258.
30. Freeman K, Colon-Rivera C, Olsson MC, Moore RL, Weinberger HD, et al. (2001) Progression from hypertrophic to dilated cardiomyopathy in mice that express a mutant myosin transgene. Am J Physiol Heart Circ Physiol 280: 151-159.
31. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, et al. (1995) The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol 27: 291-305.
32. Yamamoto S, Yang G, Zablocki D, Liu J, Hong C, et al. (2003) Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J Clin Invest 111: 1463-1474.
33. Nishida K, Yamaguchi O, Hirotani S, Hikoso S, Higuchi Y, (2004) P38 alpha mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload. Mol Cell Biol 24: 10611-10620.
34. Fentzke RC, Korcarz CE, Lang RM, Lin H, Leiden JM, (1998) Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart. J Clin Invest 101: 2415-2426.
35. Corradi D, Tchana B, Miller D, Manotti L, Maestri R, et al. (2009) Dilated form of endocardial fibroelastosis as a result of deficiency in respiratory-chain complexes I and IV. Circulation 120: e38-40.
36. Philipp S, Pagel I, Höhnel K, Lutz J, Buttgereit J, et al. (2004) Regulation of caspase-3 and Fas in pressure overload-induced left ventricular dysfunction. Eur J Heart Fail 6: 845-851.
37. Brower GL, Janicki JS, (2001) Contribution of ventricular remodeling to pathogenesis of heart failure in rats. Am J Physiol Heart Circ Physiol 280: H674-H683.
38. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, et al. (1993) Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 92: 2303-2312.
39. Lu X, Hamilton JA, Shen J, Pang T, Jones DL, et al. (2006) Role of tumor necrosis factor-alpha in myocardial dysfunction and apoptosis during hindlimb ischemia and reperfusion. Crit Care Med 34: 484-491.
40. Carlson DL, Willis MS, White DJ, Horton JW, Giroir BP, (2005) Tumor necrosis factor-alpha-induced caspase activation mediates endotoxin-related cardiac dysfunction. Crit Care Med 33: 1021-1028.
41. Araujo AS, Fernandes T, Ribeiro MF, Khaper N, Belló-Klein A, (2010) Redox regulation of myocardial ERK 1/2 phosphorylation in experimental hyperthyroidism: role of thioredoxin-peroxiredoxin system. J Cardiovasc Pharmacol 56: 513-517.
42. Communal C, Colucci WS, Remondino A, Sawyer DB, Port JD, et al. (2002) Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium. J Card Fail 8: 86-92.
43. Muchir A, Pavlidis P, Decostre V, Herron AJ, Arimura T, et al. (2007) Activation of MAPK pathways links LMNA mutations to cardiomyopathy in Emery-Dreifuss muscular dystrophy. J Clin Invest 117: 1282-1293.
44. Tenhunen O, Soini Y, Ilves M, Rysä J, Tuukkanen J, et al. (2006) p38 Kinase rescues failing myocardium after myocardial infarction: evidence for angiogenic and anti-apoptotic mechanisms. FASEB J 20: E1276-E1286.
45. Dong Y, Gao D, Chen L, Lin R, Conte JV, et al. (2006) Increased ERK activation and decreased MKP-1 expression in human myocardium with congestive heart failure. J Cardiothorac Ren Res 1: 123-130.
46. Lemke LE, Bloem LJ, Fouts R, Esterman M, Sandusky G, et al. (2001) Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK alpha is the predominant isoform expressed in human heart. J Mol Cell Cardiol 33: 1527-1540.
47. Zhuang S, Schnellmann RG, (2006) A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 319: 991-997.
48. Worou ME, Belmokhtar K, Bonnet P, Vourc'h P, Machet MC, et al. (2011) Hemin decreases cardiac oxidative stress and fibrosis in a rat model of systemic hypertension via PI3K/Akt signalling. Cardiovasc Res 91: 320-329.
49. Yaoita H, Sakabe A, Maehara K, Maruyama Y, (2002) Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. Circulation 105: 975-980.
50. Arozal W, Watanabe K, Veeraveedu PT, Ma M, Thandavarayan RA, et al. (2010) Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology 274: 18-26.
51. Ichihara S, Noda A, Nagata K, Obata K, Xu J, et al. (2006) Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovasc Res 69: 726-735.
52. Cheng CF, Juan SH, Chen JJ, Chao YC, Chen HH, et al. (2008) Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. Apoptosis 13: 883-894.
53. Chua S, Sheu JJ, Chang LT, Lee FY, Wu CJ, et al. (2008) Comparison of losartan and carvedilol on attenuating inflammatory and oxidative response and preserving energytranscription factors and left ventricular function in dilated cardiomyopathy rats. Int. Heart J 49: 605-619.
54. Li B, Liao YH, Cheng X, Ge H, Guo H, et al. (2006) Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction. Int J Cardiol 111: 247-255.
55. Palazzuoli A, Bruni F, Puccetti L, Pastorelli M, Angori P, et al. (2002) Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail 4: 765-770.
56. Zhao H, Liao Y, Minamino T, Asano Y, Asakura M, et al. (2008) Inhibition of cardiac remodeling by pravastatin is associated with amelioration of endoplasmic reticulum stress. Hypertens Res 31: 1977-1987.
57. Nakamura K, Murakami M, Miura D, Yunoki K, Enko K, et al. (2011) Beta-Blockers and Oxidative Stress in Patients with Heart Failure. Pharmaceuticals 4: 1088-1100.
58. Xu Z, Okamoto H, Akino M, Onozuka H, Matsui Y, et al. (2008) Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice. J Cardiovasc Pharmacol 51: 62-70.
59. Ojamaa K, (2010) Signaling mechanisms in thyroid hormone-induced cardiac hypertrophy. Vascul Pharmacol 52: 113-119.
60. Korecky B, Rakusan K, (1978) Normal and hypertrophic growth of the rat heart: changes in cell dimensions and number. Am J Physiol 234: H123-H128.
61. Helms SA, Azhar G, Zuo C, Theus SA, Bartke A, et al. (2010) Smaller cardiac cell size and reduced extra-cellular collagen might be beneficial for hearts of Ames dwarf mice. Int J Biol Sci 6: 475-490.